Abnormal angiogenesis in diabetes mellitus

Medicinal Research Reviews

Volumn 23, Issue 2, 2003, Pages 117-145

  Martin, Alexandra ^a   Komada, Michael R ^b   Sane, David C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Angiogenesis; Arteriogenesis; Diabetes; Vascular endothelial growth factor

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 2 ETHYL 4 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHOXY]QUINOLINE; 7 HYDROXYSTAUROSPORINE; ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ANGIOGENIN; ANGIOPOIETIN; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; INTERLEUKIN 1; LAMININ; MATRIX METALLOPROTEINASE; MIDOSTAURIN; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN;

ANGIOGENESIS; ARTERY DISEASE; ATHEROSCLEROSIS; BASEMENT MEMBRANE; CAPILLARY DENSITY; CLINICAL FEATURE; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOSYLATION; GRAFT REJECTION; HUMAN; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA NEOVASCULARIZATION; REVIEW; TUMOR VASCULARIZATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; DIABETES MELLITUS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037372172     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10024     Document Type: Review

References (168)

1. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfield RG. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001;142:1760-1769.
2. Tomanek RJ, Schatteman GC. Angiogenesis: New insights and therapeutic potential. Anat Rec 2000;261:126-135.
3. Schultz GS, Grant MB. Neovascular growth factors. Eye 1991;5:170-180.
4. Grant MB, Caballero S, Bush DM, Spoerri PE. Fibronectin fragments modulate human retinal capillary cell proliferation and migration. Diabetes 1998;47:1335-1340.
5. Aksoy H, Akcay F, Kurtul N, Baykal O, Avci B. Serum 1,25-dihydroxy vitamin D (1,25(OH)2D3), 25-hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000;33:47-51.
6. Patz A. Clinical and experimental studies on retinal neovascularization. Am J Opthalmol 1982;94:715-743.
7. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment. Invest Opthalmol Vis Sci 2000;41:2115-2119.
8. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000;58:S113-S119.
9. Rand RI. Recent advances in diabetic retinopathy. Am J Med 1981;70:595-602.
10. Williamson JR, Chang K, Rowold E, Marvel J, Tomlinson M, Sherman WR, Ackermann KE, Kilo C. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking. Diabetes 1985;34:703-705.
11. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-912.
12. Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS. Harrison's principles of internal medicine edition 11. New York: McGraw-Hill; 1987.
13. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 1996;81:1940-1945.
14. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
15. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993;36:189-194.
16. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44:1139-1146.
17. Loots MAM, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 1999;291:93-99.
18. Loots MAM, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middlekoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetes and venous ulcers venous acute wounds. J Invest Dermatol 1998;111:850-857.
19. Shyng YC, Devlin H, Sloan P. The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. Int J Oral Maxillofac Surg 2001;30:70-74.
20. Galeano M, Torre V, Deodato B, Campo GM, Colonna M, Sturiale A, Squadrito F, Cavallari V, Cucinotta D, Buemi M, Altavilla D. Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. Surgery 2001;129:467-477.
21. Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodata B, Colonna M, Torre V, Russo G, Sardella A, Urna G, Campo GM, Cavallari V, Squadrito G, Squadrito F. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001;50:667-674.
22. Ferguson MWJ, Herrick SE, Spencer MJ, Shaw JE, Boulton AJM, Sloan P. The histology of diabetic foot ulcers. Diabetes Medicine 1996;13:S30-S33.
23. Waltenberger J. Impaired collateral vessel development in diabetes: Potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001;49:554-560.
24. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363.
25. Abachi A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes millitus on the formation of coronary collateral vessels. Circulation 1999;99:2239-2242.
26. Yarom R, Zirkin H, Stammler G, Rose AG. Human coronary microvessels in diabetes and ischemia. Morphometric study of autopsy material. J Pathol 1992;166:265-270.
27. Barzilai JI, Kronmall RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients age > 65 years (Report from Coronary Artery Surgery Study (CASS) Registry). Am J Cardiol 1994;74:334.
28. Abaci A, Ogushan A, Kahraman S, Eryol NK, Ünal S, Hüseyin A, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242.
29. Melidonis A, Tournis S, Kouvaras G, Baltaretsou E, Hadanis S, Hajissavas I, Tsatsoulis A, Foussas S. Comparison of coronary collateral circulation in diabetic nondiabetic patients suffering from coronary artery disease. Clin Cardiol 1999;22:465-471.
30. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363.
31. Baker L, Piddington R. Diabetic embryopathy: A selective review of recent trends. J Diabetes Complications 1993;7:404-412.
32. Cockroft DL, Coppola PT. Teratogenic effects of excess glucose on head-fold rat embryos in culture. Teratology 1977;16:141-146.
33. Eriksson UJ, Hakan-Borg LA, Forsberg H, Styrud J. Diabetic embryopathy: Studies with animal and in vitro models. Diabetes 1991;40:94-98.
34. Pinter E, Reece EA, Leranth CZ, Sanyal MK, Hobbins JC, Mahoney MJ, Naftolin F. Yolk sac failure in embryopathy due to hyperglycemia: Ultrastructural analysis of yolk sac differentiation associated with embryopathy in rat conceptuses under hyperglycemic conditions. Teratology 1986;33:73-84.
35. Reece EA, Homko CJ. Multifactorial basis of the syndrome of diabetic embryopathy. Teratology 1996;54:171-182.
36. Ferencz C, Rubin JD, McCarter RJ, Clark EB. Maternal diabetes and cardiovascular malformations: Predominance of double outlet right ventricle and truncus arteriosis. Teratology 1990;41:319-326.
37. Pinter E, Mahooti S, Wang Y, Imhof BA, Madri JA. Hyperglycemia-induced vasculopathy in the murine vitelline vasculature: Correlation with PECAM 1/CD31 tyrosine phosphorylation state. Am J Pathol 1999;154:1367-1379.
38. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-210.
39. Clarke DE, Smith SK, Sharkey AM, Charnock-Jones DS. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996;11:1090-1098.
40. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995;203:80-92.
41. Zygmunt M. Placental circulation: Clinical significance. Early Pregnancy 2001;5:72-73.
42. Vasir B, Reitz P, Xu G, Sharma A, Bonner-Weir S, Weir GC. Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. Diabetologia 2000;43:763-772.
43. Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC. Vulnerability of islets in the immediate posttransplantation period: Dynamic changes in structure and function. Diabetes 1996;45:1161-1167.
44. Juang J-H, Bonner-Weir S, Wu Y-J, Weir GC. Beneficial influence of glycemic control upon the growth and function of transplanted islets. Diabetes 1995;43:1334-1339.
45. Korsgren O, Jansson L, Andersson A. Effects of hyperglycemia on function of isolated mouse pancreatic islets transplanted under kidney capsule. Diabetes 1989;38:510-515.
46. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: A case-control study. Hepatology 2001;34:889-895.
47. Kim H, Cheigh JS. Kidney transplantation in patients with type 1 diabetes mellitus: Long-term prognosis for patients and grafts. Korean J Intern Med 2001;16:98-104.
48. Menger MD, Jaeger S, Walter P, Feifel G, Hammersen F, Messmer K. Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans. Diabetes 1989;38:199-201.
49. Vasir B, Jonas JC, Steil GM, Hollister-Lock J, Hasenkamp W, Sharma A, Bonner-Weir S, Weir GC. Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. Transplantation 2001;71:924-935.
50. Kawakami Y, Iwata H, Gu YJ, Miyamoto M, Murakami Y, Balamurugan AN, Imamura M, Inoue K. Successful subcutaneous pancreatic islet transplantation using an angiogenic growth factor releasing device. Pancreas 2001;23:375-381.
51. Cross SE, Thompson MJ, Roberts MS. Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment. Antimicrob Agents Chemother 1996;40:1703-1710.
52. Cameron NE, Cotter MA, Robertson S. Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozotocin-induced diabetic rats. Diabetes 1991;40:532-539.
53. Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve finction. Diabetologia 1993;36:1230-1237.
54. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic andbstreptozotocin-diabetic rats. Diabetologia 1994;37:449-459.
55. Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: A role for the microcirculation? Diabet Med 1992;9:320-329.
56. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995;96:1159-1163.
57. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;49:1006-1015.
58. Jack AM, Cameron NE, Cotter MA. Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats. J Diabetes Complications 1999;13:2-9.
59. Cameron NE, Cotter MA. Interaction between oxidative stress and gamma-linolenic acid in impaired neurovascular function of diabetic rats. Am J Physiol 1996;271:E471-E476.
60. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992;35:12-18.
61. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borsch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-1365.
62. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Opthalmol Soc UK 1948;68:137-180.
63. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503.
64. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Opthalmol 1996;114:971-977.
65. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
66. Mattei MG, Borg JP, Rosnet O, Marme D, Birnbaum D. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-P21 and 14q24-Q31 regions, respectively. Genomics 1996;32:168-169.
67. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Opthalmology 1996;103:1820-1828.
68. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab 1998;24:400-405.
69. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-268.
70. Pu X, Aiello LP, Jiang ZY, Park DJ, Newsome WP, King GL. Characterization of vascular endothelial growth factors effect on the activation of phospholipase C, protein kinase C pathways and endothelial cell growth. J Clin Invest 1996;98:2018-2026.
71. Stark J, Baffour R, Garb JL, Kaufman J, Berman J, Rhee S, Norris MA, Friedmann P. Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. J Surg Res 1998;79:8-12.
72. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-beta-1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000;278:F628-F634.
73. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasqualle LR, Thieme H, Iwamoto MA, Parke JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
74. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van De Water L, Senger DR, Dvorak HF, Rosen S. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457-1461.
75. Simon M, Gröne HJ, Jöhren O, Kullmer J, Plate KH, Risau W, Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal outogenesis and in adult kidney. Am J Physiol 1995;268: F240-F250.
76. 125I] VEGF binding sites. J Am Soc Nephrol 1998;9:1032-1044.
77. Brenchley PE. VEGF/VPF: A modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996;9:10-17.
78. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-2239.
79. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000.
80. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation and product inhibitor, OPB-9195. Diabetologia 1999;42:579-588.
81. Williams B, Gallacher B, Patel H, Ormic C. Glucose-induced protein kinase C activation regulates vascular permeability factor MRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503.
82. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-H1058.
83. Veelken R, Hilgers KF, Hartner A, Haas A, Böhmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000;11:71-79.
84. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathofenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994;43:1190-1197.
85. Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 1996;74:136-143.
86. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993;36:189-194.
87. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
88. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-912.
89. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:854-860.
90. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Hans-Henrik P, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
91. Hans-Henrik P, Lwhnert H, Brochner-Mortensen J, Gomis R, Anderson S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
92. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
93. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
94. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
95. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, Viberti G. Interaction of angiotensin II and mechanical stretch on vascular nedothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999;10:730-737.
96. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-255.
97. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoitin-2 vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001;88:22-29.
98. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME. Angiotensin converting enzyme inhibition reduced retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1367.
99. Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, Honda Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41:1192-1199.
100. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997;273:H2224-H2231.
101. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab 1998;24:400-405.
102. Malamitsi-Puchner A, Saradakou A, Dafogianni C, Tziotis J, Bartsocas CS. Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus. Pediatr Res 1998;43:798-800.
103. Zimering MB, Eng J. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endocrinol Metab 1996;81:4446-4452.
104. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 1996;81:1940-1945.
105. Zimering MB, Eng J. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endocrinol Metab 1996;81:4446-4452.
106. Hill DJ, Petrik J, Arany E. Growth factors and the regulation of fetal growth. Diabetes Care 1998;21:B60-B69.
107. Itoh H, Mukoyama M, Pratt R, Gibbons G, Dzau V. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993;91:2268-2274.
108. Casaroli-Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin, and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995;60:5-17.
109. Preissner KT, Kanse SM, Hammes HP. Integrin chatter and vascular function in diabetic retinopathy. Horm Metab Res 1997;29:643-645.
110. Stromblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996;6:462-467.
111. Voet D, Voet JD. Biochemistry. New York: John Wiley & Sons; 1990.
112. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose modified proteins: A potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991;174:931-939.
113. Fonseca V, Munshi M, Merin LM, Bradford JD. Diabetic retinopathy: A review for the primary care physician. South Med J 1996;89:839-850.
114. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-146.
115. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah St, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 1994;331:1519-1520.
116. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-43841.
117. Teixeira AS, Caliari MV, Rocha OA, Machado RD, Andrade SP. Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats. Inflammation 1999;23:59-81.
118. Halvoresen YD, Bursell SE, Wilkison WO, Clermont AC, Brittis M, McGovern TJ, Spiegelman BM. Vasodilation of rat retinal microvessels induced by monobutyrin. Dysregulation in diabetes. J Clin Invest 1993;92:2872-2876.
119. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissue of obese mice. Proc Natl Acad Sci USA 1998;95:7591-7696.
120. Kampfer H, Pfeilschifter J, Frank S. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: A comparative study of normal and impaired repair. Lab Invest 2001;81:361-373.
121. Frank S, Hubner G, Breier G, Londaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1995;270:12607-12613.
122. Bitar MS, Labbad ZN. Transforming growth factor-beta and insulin-like growth factor-1 in relation to diabetes-induced impairment of wound healing. J Surg Res 1996;61:113-119.
123. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release form quiescent rabbit and human vascular endothelium. Circulation 1997;95:1030-1037.
124. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995;15:1255-1261.
125. Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, Stewart DJ. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998;82:1007-1015.
126. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
127. Vallance P, Leone A, Claver A, Collier J, Moncada S. Endogenous dimethlarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20:S60-S62.
128. Vallance P, Leone A, Claver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
129. Fickling SA, Leone AM, Nussey SS, Vallance P, Whitley GS. Synthesis of NG, NG-dimethylarginine by human endothelial cells. Endothelium 1993;1:137-140.
130. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
131. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
132. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen N, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thorm Vasc Biol 2000;20:2039-2044.
133. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscl Thromb Vasc Biol 2000;20:2032-2037.
134. Jang JJ, Ho HK, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia: Role of asymmetric dimethylarginine. Circulation 2000;102:1414-1419.
135. Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr 2000;130:2626-2629.
136. Cohen RA. Dysfunction of the vascular endothelium in diabetes mellitus. Circulation 1993;87:V67-V76.
137. Schaper W, Buschmann I. Collateral circulation and diabetes. Circulation 1999;99:2224-2226.
138. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. A potential predictor for the individual capacity to develop collaterals. Circulation 2000;102:185-190.
139. Waltenberger J. Impaired collateral vessel development in diabetes: Potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001;49:554-560.
140. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP. Interindividual heterogeneity in the hypoxic regulation of VEGF. Significance for the development of the coronary artery collateral circulation. Circulation 1999;100:547-552.
141. Takeuchi K, Takehara K, Tajima K, Kato S, Hirata T. Impaired healing of gastric lesions in streptozotocin-induced diabetic rats: Effect of basic fibroblast growth factor. J Pharmacol Exp Ther 1997;281:200-207.
142. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997;81:567-574.
143. Cooke JP. The pathophysiology of peripheral arterial disease: Rational targets for drug intervention. Vasc Med 1997;2:227-230.
144. Malamitsi-Puchner A, Sarandakou A, Dafogianni C, Tziotis J, Bartsocas CS. Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus. Pediatr Res 1998;43:798-800.
145. McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, Barbour R, Demetriou AA. Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res 1988;45:145-153.
146. Sun L, Xu L, Chang H, Henry FA, Miller RM, Harmon JM, Nielsen TB. Transfection with aFGF cDNA improves wound healing. J Invest Dermatol 1997;108:313-318.
147. Mellin TN, Cashen DE, Ronan JJ, Murphy BS, DiSalvo J, Thomas KA. Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice. J Invest Dermatol 1995;104:850-855.
148. Giordano FJ, Ping P, McKiman MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539.
149. Vranes D, Dilley RJ, Cooper ME. Vascular changes in the diabetic kidney: Effects of ACE inhibition. J Diabetes Complications 1995;9:296-300.
150. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
151. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
152. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
153. Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during β-adrenergic blockade in IDDM. Diabetes 1991;40:1177-1186.
154. Popp DA, Shah SD, Cryer PE. Role of epinepherine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. J Clin Invest 1982;69:315-326.
155. Williamson JR, Chang K, Rowold E, Marvel J, Tomlinson M, Sherman WR, Ackermann KE, Kilo C. Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil. Metabolism 1986;35:41-45.
156. Shizukuda Y, Tang S, Yokota R, Ware A. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase C5 activity. Circ Res 1999;85:247-256.
157. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412 - A protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
158. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.
159. Wang A, Nomura M, Patan S, Ware JA. Inhibition of protein kinase C alpha prevents endotheilial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo. Circ Res 2002;90:609-616.
160. Ido Y, Chang KC, Lejeune WS, Bjercke RJ, Reiser KM, Williamson JR, Tilton RG. Vascular dysfuncion induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 2001;8:251-263.
161. Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997;8:426-435.
162. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
163. Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis 1998-1999;18:209-218.
164. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001;38:S178-S181.
165. Spiegelman A. PPAR6 in monocytes: Less pain, any gain? Cell 1998;93:153-155.
166. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, Asch AS. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med 2001;7:840-846.
167. Teixeira AS, Andrade SP. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 1999;64:655-662.
168. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney International 1996;50:148-155.